Kevin Shannon spends much of his time researching Cancer research, Leukemia, Neurofibromin 1, Juvenile myelomonocytic leukemia and Myeloid. His Cancer research study combines topics from a wide range of disciplines, such as Haematopoiesis, Stem cell, KRAS, PTPN11 and Signal transduction. His Leukemia research is within the category of Immunology.
His Neurofibromin 1 research includes elements of Tumor suppressor gene and Allele. In most of his Juvenile myelomonocytic leukemia studies, his work intersects topics such as Mutation. His Myeloid research includes themes of Myelogenous, Myeloproliferative Disorders and Bone marrow.
Kevin Shannon focuses on Cancer research, Myeloid, Leukemia, Immunology and Internal medicine. His Cancer research research incorporates elements of Haematopoiesis, Stem cell, KRAS, Neuroblastoma RAS viral oncogene homolog and Signal transduction. His Haematopoiesis research is multidisciplinary, relying on both Progenitor cell and MAPK/ERK pathway.
In Myeloid, Kevin Shannon works on issues like Bone marrow, which are connected to Somatic cell. Kevin Shannon has researched Leukemia in several fields, including Juvenile myelomonocytic leukemia, Myeloid leukemia, MEK inhibitor and Neurofibromin 1. His Immunology study frequently draws connections to adjacent fields such as Neurofibromatosis.
Kevin Shannon mainly focuses on Cancer research, Internal medicine, Cardiology, Myeloid and Myeloid leukemia. The Cancer research study combines topics in areas such as Cancer, Leukemia, Immunology and KRAS, Neuroblastoma RAS viral oncogene homolog. His work in KRAS tackles topics such as Carcinogenesis which are related to areas like Allele.
As part of the same scientific family, Kevin Shannon usually focuses on Internal medicine, concentrating on Surgery and intersecting with Fontan procedure. His research in Myeloid focuses on subjects like Haematopoiesis, which are connected to Progenitor cell. His research on Myeloid leukemia also deals with topics like
His scientific interests lie mostly in Cancer research, Internal medicine, Myeloid, Cardiology and Leukemia. His Cancer research research includes themes of T cell, KRAS, Combination therapy, Cytotoxic T cell and PI3K/AKT/mTOR pathway. His Myeloid study integrates concerns from other disciplines, such as Neurofibromin 1, Haematopoiesis, Myeloproliferative Disorders and Chromosome 7.
He interconnects Hematology, Bone marrow, Germline and Somatic cell in the investigation of issues within Chromosome 7. His Cardiology course of study focuses on Surgery and Heart disease. His biological study spans a wide range of topics, including AMPK, Myeloid leukemia, Stem cell and Janus kinase 2.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hyperactive Ras in developmental disorders and cancer.
Suzanne Schubbert;Kevin Shannon;Gideon Bollag.
Nature Reviews Cancer (2007)
Germline KRAS mutations cause Noonan syndrome
Suzanne Schubbert;Martin Zenker;Sara L . Rowe;Silke Böll.
Nature Genetics (2006)
The Rate of Telomere Sequence Loss in Human Leukocytes Varies with Age
Robert W. Frenck;Elizabeth H. Blackburn;Kevin M. Shannon.
Proceedings of the National Academy of Sciences of the United States of America (1998)
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
G. Bollag;D. W. Clapp;S. Shih;F. Adler.
Nature Genetics (1996)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M Haigis;Krystle R Kendall;Yufang Wang;Ann Cheung.
Nature Genetics (2008)
Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
Kevin M. Shannon;Peter O'Connell;George A. Martin;Dorothy Paderanga.
The New England Journal of Medicine (1994)
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Mignon L. Loh;Shashaank Vattikuti;Suzanne Schubbert;Melissa G. Reynolds.
Blood (2004)
Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
K M Shannon;J F Keith rd;W C Mentzer;R A Ehrenkranz.
Pediatrics (1995)
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Benjamin S. Braun;David A. Tuveson;Namie Kong;Doan T. Le.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Homozygous Inactivation of the NF1 Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders
Lucy Side;Brigit Taylor;Matthew Cayouette;Edward Conner.
The New England Journal of Medicine (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of California, San Francisco
University of Chicago
University of Minnesota
St. Jude Children's Research Hospital
MIT
University of California, Los Angeles
Stanford University
University of Freiburg
Otto-von-Guericke University Magdeburg
Memorial Sloan Kettering Cancer Center
University of Genoa
Purdue University West Lafayette
Massey University
Georgia Institute of Technology
University of Illinois at Urbana-Champaign
MSD (United States)
KTH Royal Institute of Technology
West Virginia University
University of Birmingham
Johns Hopkins University
Institut de Recherche pour le Développement
Washington University in St. Louis
University of Vienna
National Institutes of Health
Monash University
University of Bristol